{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:02:04Z","timestamp":1761487324259,"version":"3.44.0"},"reference-count":35,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Fam Plann Reprod Health Care"],"accepted":{"date-parts":[[2000,10,2]]},"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Systemic lupus erythematosus (SLE) is an autoimmune oestrogen-mediated disease. Antiphospholipid syndrome (APS) is an autoimmune acquired thrombophilia. These two conditions may co-exist and are most frequently diagnosed in young women. Hormonal contraception may promote lupus activity and thromboses. Medical practitioners may not know what advice to give these women regarding contraception.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the past and present contraceptive practices of women with SLE and\/or APS, and to establish the incidence of complications related to use of various contraceptives. Also, the contraceptive information given to women following diagnosis was evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study design<\/jats:title>\n                  <jats:p>Observational questionnaire-based study of 86 women with SLE and\/or APS attending the Lupus\/Thrombophilia Clinics at St. Thomas' Hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One of the 19 (5%) women with SLE using the combined oral contraceptive pill (COCP) at the time of diagnosis reported a severe lupus 'flare'. Seven of the 32 (22%) women with APS using the COCP suffered from thromboses during use. There were no problems specific to women with SLE and\/or APS using any other form of contraception. Thirty-nine (45%) women received no contraceptive information following their diagnosis, 37 (46%) were told to avoid the COCP due to the increase in lupus 'flare' and\/or thromboses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There is no clinically significant association between COCP use and lupus 'flare'. The high incidence of thromboses in women with APS using the COCP containing either second or third generation progestogens suggests that these women should be advised against using this form of contraception. Women with SLE and\/or APS should be given more information about contraceptive issues.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1783\/147118901101195029","type":"journal-article","created":{"date-parts":[[2005,3,5]],"date-time":"2005-03-05T01:30:57Z","timestamp":1109986257000},"page":"7-12","source":"Crossref","is-referenced-by-count":28,"title":["Contraceptive practices in women with systemic lupus erythematosus and\/or antiphospholipid syndrome: What advice should we be giving?"],"prefix":"10.1136","volume":"27","author":[{"given":"Lorin","family":"Lakasing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munther","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2001,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients","volume":"72","author":"Cevera, R.; Khamashta, M.A.; Font, J.","year":"1993","unstructured":"Cevera R, Khamashta MA, Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Med 1993; 72: 113\u2013138.","journal-title":"Med"},{"key":"ref_2","first-page":"1162","article-title":"Sex hormone modulation of autoimmunity in NZB\/NZW mice","volume":"22","author":"Roubinian, J.; Talal, N.; Siiteri, P.K.","year":"1979","unstructured":"Roubinian J, Talal N, Siiteri PK, et al. Sex hormone modulation of autoimmunity in NZB\/NZW mice. Arthritis Rheum 1979; 22: 1162\u20131169.","journal-title":"Arthritis Rheum"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/art.1780221103","article-title":"Approach to the study of the role of sex hormones in autoimmunity","volume":"22","author":"Steinberg, A.D.; Melez, K.A.; Raveche, E.S.","year":"1979","unstructured":"Steinberg AD, Melez KA, Raveche ES, et al. Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum 1979; 22: 1170\u20131176.","journal-title":"Arthritis Rheum"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/1529-0131(199810)41:10<1714::AID-ART3>3.0.CO;2-U","article-title":"environmental and infectious risk factors for developing systemic lupus erythematosus","volume":"41","author":"Cooper, G.S.; Dooley, M.A.; Treadwell, E.L.","year":"1998","unstructured":"Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1714\u20131724.","journal-title":"Arthritis Rheum"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/rheumatology\/35.2.133","article-title":"Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies","volume":"35","author":"Ruiz-Irastorza, G.; Lima, F.; Alves, J.","year":"1996","unstructured":"Ruiz-Irastorza G, Lima F, Alves J, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35: 133\u2013138.","journal-title":"Br J Rheumatol"},{"key":"ref_6","first-page":"893","article-title":"Lupus pregnancy - case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy","volume":"77","author":"Lockshin, M.D.; Reinitz, E.; Murrman, M.","year":"1984","unstructured":"Lockshin MD, Reinitz E, Murrman M, et al. Lupus pregnancy - case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med 1984; 77: 893\u2013898.","journal-title":"Am J Med"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/anr.1780320602","article-title":"Pregnancy does not cause systemic lupus erythematosus to worsen","volume":"32","author":"Lockshin, MD","year":"1989","unstructured":"Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 1989; 32: 665\u2013670.","journal-title":"Arthritis Rheum"},{"key":"ref_8","first-page":"1333","article-title":"Does prolactin have a role in the pathogenesis of systemic lupus erythematosus?","volume":"19","author":"Jara, L.J.; Lavalle, C.; Espinoza, L.R.","year":"1992","unstructured":"Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J Rheumatol 1992; 19: 1333\u20131336.","journal-title":"J Rheumatol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780250603","article-title":"Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus","volume":"25","author":"Jungers, P.; Dougados, M.; Pelissier, C.","year":"1982","unstructured":"Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618\u2013623.","journal-title":"Arthritis Rheum"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780400504","article-title":"Oral contraceptives and systemic lupus erythematosus","volume":"40","author":"Petri, M.; Robinson, C.","year":"1997","unstructured":"Petri M, Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1997; 40: 797\u2013803.","journal-title":"Arthritis Rheum"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/art.1780400505","article-title":"Past use of oral contraceptives and the risk of developing systemic lupus erythematosus","volume":"40","author":"Sanchez-Guerrero, J.; Karlson, E.W.; Liang, M.H.","year":"1997","unstructured":"Sanchez-Guerrero J, Karlson EW, Liang MH, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40: 804\u2013808.","journal-title":"Arthritis Rheum"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90108-2","article-title":"Comparison of primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients","volume":"96","author":"Vianni, J.; Khamashta, M.A.; Ordi-Ros, J.","year":"1994","unstructured":"Vianni J, Khamashta MA, Ordi-Ros J, et al. Comparison of primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3\u20139.","journal-title":"Am J Med"},{"article-title":"Faculty of Family Planning and Reproductive Health Care and Family Planning Association Joint Statement in response to the CSM letter of","year":"1995","key":"ref_13","unstructured":"Faculty of Family Planning and Reproductive Health Care and Family Planning Association Joint Statement in response to the CSM letter of 18 October 1995. 26 October 1995."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low dose oral contraceptives on venous thromboembolic disease","volume":"346","year":"1995","unstructured":"World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low dose oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582\u20131588.","journal-title":"Lancet"},{"key":"ref_15","article-title":"Committee on Safety of Medicines. Combined oral contraceptives and thromboembolism","volume-title":"Letter","year":"1995","unstructured":"Committee on Safety of Medicines. Combined oral contraceptives and thromboembolism. Letter 18 October 1995."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/03009749109096822","article-title":"Oral contraceptives in systemic lupus erythematosus: side-effects and the influence on activity of SLE","volume":"20","author":"Julkunen, H.A.","year":"1991","unstructured":"Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side-effects and the influence on activity of SLE. Scand J Rheumatol 1991; 20: 427\u2013433.","journal-title":"Scand J Rheumatol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/art.1780310424","article-title":"Complications of oral contraceptives and antiphospholipid antibodies","volume":"31","author":"Asherton, R.A.; Harris, E.N.; Hughes, G.R.V.","year":"1988","unstructured":"Asherton RA, Harris EN, Hughes GRV, et al. Complications of oral contraceptives and antiphospholipid antibodies. Arthritis Rheum 1988; 31: 575\u2013576.","journal-title":"Arthritis Rheum"},{"key":"ref_18","first-page":"372","article-title":"Clinical consequences of antiphospholipid antibodies: an historic cohort study","volume":"83","author":"Silver, R.M.; Draper, M.L.; Scott, JR","year":"1994","unstructured":"Silver RM, Draper ML, Scott JR, et al. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol 1994; 83: 372\u2013377.","journal-title":"Obstet Gynecol"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/096120398678919624","article-title":"Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients","volume":"7","author":"Shah, N.; Khamashta, M.A.; Atsumi, T.","year":"1998","unstructured":"Shah N, Khamashta MA, Atsumi T, et al. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998; 7: 3\u20136.","journal-title":"Lupus"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/32.3.227","article-title":"Contraceptive practice in women with systemic lupus erythematosus","volume":"32","author":"Julkunen, H.A.; Kaaja, R.; Friman, C.","year":"1993","unstructured":"Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women with systemic lupus erythematosus. Br J Rheum 1993; 32: 227\u2013230.","journal-title":"Br J Rheum"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/art.1780291020","article-title":"Antibodies to cardiolipin and vascular complications in women taking oral contraceptives","volume":"29","author":"Bruneau, C.; Intrator, L.; Sobel, A.","year":"1986","unstructured":"Bruneau C, Intrator L, Sobel A, et al. Antibodies to cardiolipin and vascular complications in women taking oral contraceptives. Arthritis Rheum 1986; 29: 1294.","journal-title":"Arthritis Rheum"},{"key":"ref_22","first-page":"1271","article-title":"revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan, E.M.; Cohen, A.S.; Fries, J.F.","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271\u20131277.","journal-title":"The"},{"key":"ref_23","first-page":"501","article-title":"Rheumatic disease, abnormal serology and oral contraceptives","volume":"2","author":"Tarzy, B.J.; Garcia, C.R.; Wallach, E.E.","year":"1972","unstructured":"Tarzy BJ, Garcia CR, Wallach EE, et al. Rheumatic disease, abnormal serology and oral contraceptives. Lancet 1972; 2: 501\u2013503.","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0002-9378(71)90730-7","article-title":"Oral contraceptives and exacerbation of lupus erythematosus","volume":"110","author":"Chapel, T.A.; Burns, R.E.","year":"1971","unstructured":"Chapel TA, Burns RE. Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol 1971; 110: 366\u2013369.","journal-title":"Am J Obstet Gynecol"},{"key":"ref_25","first-page":"732","article-title":"Prospective study of pregnancy in systemic lupus erythematosus: results of a multidisciplinary approach","volume":"13","author":"Mintz, G.; Niz, J.; Gutierrez, G.","year":"1986","unstructured":"Mintz G, Niz J, Gutierrez G, et al. Prospective study of pregnancy in systemic lupus erythematosus: results of a multidisciplinary approach. J Rheumatol 1986; 13: 732\u2013739.","journal-title":"J Rheumatol"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0010-7824(84)90076-3","article-title":"Contraception with progestagens in systemic lupus erythematosus","volume":"30","author":"Mintz, G.; Gutierrez, C.; Deleze, M.","year":"1984","unstructured":"Mintz G, Gutierrez C, Deleze M, et al. Contraception with progestagens in systemic lupus erythematosus. Contraception 1984; 30: 29\u201330.","journal-title":"Contraception"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/bmj.2.5703.203","article-title":"Thromboembolic disease and the steroidal content of oral contraceptives: a report on to the Committee on Safety of Drugs","volume":"2","author":"Inman, W.H.W.; Vessey, M.P.; Westerholm, B.","year":"1970","unstructured":"Inman WHW, Vessey MP, Westerholm B, et al. Thromboembolic disease and the steroidal content of oral contraceptives: a report on to the Committee on Safety of Drugs. Br Med J 1970; 2: 203\u2013209.","journal-title":"Br Med J"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0002-9378(16)32485-1","article-title":"Progestogens and arterial disease: evidence from the Royal College of General Practitioners\u2019","volume":"142","author":"Kay, C.R.","year":"1982","unstructured":"Kay CR. Progestogens and arterial disease: evidence from the Royal College of General Practitioners\u2019 study. Am J Obstet Gynecol 1982; 142: 762\u2013765.","journal-title":"study. Am J Obstet Gynecol"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM199607043350102","article-title":"Stroke in users of low-dose oral contraceptives","volume":"335","author":"Petitti, M.; Sidney, S.; Berstein, A.","year":"1996","unstructured":"Petitti M, Sidney S, Berstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335: 8\u201315.","journal-title":"N Engl J Med"},{"key":"ref_30","first-page":"41","article-title":"Trends in use of oral contraceptives in Britain","volume":"16","author":"Thorogood, M.; Vessey, M.P.","year":"1990","unstructured":"Thorogood M, Vessey MP. Trends in use of oral contraceptives in Britain. Br J Fam Plan 1990; 16: 41\u201353.","journal-title":"Br J Fam Plan"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0002-9378(94)05014-3","article-title":"Coagulation and anticoagulation effects of contraceptive steroids","volume":"170","author":"Samsioe, G.","year":"1994","unstructured":"Samsioe G. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 1994; 170: 1523\u20131527.","journal-title":"Am J Obstet Gynecol"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91926-0","article-title":"World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study","volume":"346","year":"1995","unstructured":"World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1995; 346: 1575\u20131582.","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components","volume":"346","author":"Jick, H.; Jick, S.S.; Gurewich, V.","year":"1995","unstructured":"Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995; 346: 1589\u20131593.","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study","volume":"312","author":"Spitzer, W.O.; Lewis, M.A.; Heinemann, L.A.J.","year":"1996","unstructured":"Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83\u201388.","journal-title":"Br Med J"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third generation progestagen","volume":"346","author":"Bloemencamp, K.W.M.; Rosendaal, F.R.; Helmerhorst, F.M.","year":"1995","unstructured":"Bloemencamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995; 346: 1593\u20131596.","journal-title":"Lancet"}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1783\/147118901101195029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:23:56Z","timestamp":1757100236000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1783\/147118901101195029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2001,1,1]]},"published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1783\/147118901101195029"],"URL":"https:\/\/doi.org\/10.1783\/147118901101195029","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"type":"print","value":"1471-1893"},{"type":"electronic","value":"2045-2098"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}